In vivo pharmacology of irindalone, a 5-HT2receptor antagonist with predominant peripheral effects
- 1 January 1989
- journal article
- research article
- Published by Wiley in Drug Development Research
- Vol. 16 (1) , 59-70
- https://doi.org/10.1002/ddr.430160107
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Neurochemical profile in vitro of irindalone: A5-HT2-receptor antagonistDrug Development Research, 1988
- Neuropharmacological reassessment of the discriminative stimulus properties ofd-lysergic acid diethylamide (LSD)Psychopharmacology, 1987
- Adaptive changes in the 5-HT2 binding site after chronic administration of agonists and antagonistsNeuropharmacology, 1986
- Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamineNeuropharmacology, 1986
- Differential Effect of Subchronic Treatment with Various Neuroleptic Agents on Serotonin2 Receptors in Rat Cerebral CortexJournal of Neurochemistry, 1986
- The pharmacology of ketanserin, the first selective serotonin S2‐antagonistDrug Development Research, 1985
- The Citalopram/5‐HTP‐induced Head Shake Syndrome is Correlated to 5‐HT2 Receptor Affinity and also Influenced by other TransmittersActa Pharmacologica et Toxicologica, 1984
- Neuroleptic activity and dopamine-uptake inhibition in 1-piperazino-3-phenylindansJournal of Medicinal Chemistry, 1983
- 5-HT2 receptor blockade to study serotonin-induced pathologyTrends in Pharmacological Sciences, 1983
- In vivo binding of [3H]ketanserin on serotonin S2-receptors in rat brainEuropean Journal of Pharmacology, 1982